A.O. Lobkarev – Ph.D. (Med.), Urologist, Clinic of ambulatory urology (Kazan)  E-mail: lobkarev@gmail.com  

Introduction. The scarcity of revealed pathologic changes is one of the features of chronic prostatitis 3B (CP3B). The basic criteria of diagnostics do not have the clear outlines and interpretation. These circumstances determine the low level of understanding the problem of CP3B, the difficulties of evaluation of the patient’s status. They are the reasons for the hardships in development of new methods of treatment in men with CP3B. For objective assessment of the functional status of prostatic tissue, the «KAlium Parameter of Laboratory analysis, Evaluating in Ejaculate (KAPLEE)», was offered. KAPLEE is the concentration of K+ ions, measuring with the help of potentiometry in 42 ml of water solution, which contains 1 ml of ejaculate, 39 ml of distilled water and 2 ml of special buffer solution. The aim – to check the hypothesis that the deviation of KAPLEE from the normal range towards reduction or towards increase is the predictor of less effectiveness of tamsulosin in patients with CP3B. 

Materials and methods. In trial 32 patients with the diagnosis of CP3B, who received tamsulosin 0,4 mg once a day for 30 days as monotherapy, took part. During first stage each patient evaluated the effectiveness of this pharmacotherapy in his case; it varied from 1 point (absolute non-effectiveness) to 5 points (absolute effectiveness). Then each patient ejaculated in container, and the concentration of KAPLEE was measured. Thus, the data of each patient were placed in two-axial system of coordinates: axis of abscisses was the concentration of KAPLEE, axis of ordinates was the mark of effectiveness. Then the cluster analysis of these data was made. 

Results and conclusion. The concentration of kalium in ejaculate is the predictor of tamsulosin effectiveness in men with CP3B. Normal values of KAPLEE are associated with high effectiveness of tamsulosin, its deviations are predictors of low effectiveness. 

1. Krupin V.N., Krupin A.V., Belova A.N. Patogeneticheskoe lechenie bol'nyh hronicheskim bakterial'nym prostatitom s soputstvuyushchej nevrologicheskoj patologiej: nash opyt // Urologicheskie vedomosti. 2018. T. 8. № 3. S. 36–43. DOI: 10.17816/uroved8336-43.
2. Vinarov A.Z. Sovremennye predstavleniya ob ehtiologii, patogeneze i lechenii sindroma hronicheskoj tazovoj boli // Urologiya. 2017. № 1.  S. 114–122. DOI: 10.18565/urol.2017.1.114-122.
3. Loran O.B., Segal A.S. Sistema summarnoj ocenki simptomov pri hronicheskom prostatite // Urologiya. 2001. № 5. S. 16–19.
4. Al'-SHukri S.H., Gorbachev A.G., Borovec S.YU. i dr. K patogenezu i profilaktike hronicheskogo prostatita (kliniko-ehksperimental'noe issledovanie) // Urologicheskie vedomosti. 2012. T. 2. № 2. S. 15–19.
5. Tkachuk V.N., Al'-SHukri A.S., Tkachuk I.N., Sternin YU.I. Rezul'taty 10-letnego issledovaniya ehffektivnosti proteoliticheskih ehnzimov u bol'nyh hronicheskim prostatitom // Urologicheskie vedomosti. 2015. T. 5. № 2. S. 5–9. 
6. Kogan M.I., Macionis A.EH., Belousov I.I., Povilajtite P.E. Morfologicheskie dokazatel'stva ishemicheskoj prirody fibroza predstatel'noj zhelezy pri klassicheskom sindrome hronicheskoj tazovoj boli / hronicheskom prostatite IIIB // Urologiya. 2018. № 3. S. 12–19. DOI: 10.18565/ urology.2018.3.12-18. 
7. Kamalov A.A., Spivak L.G., Gamidov S.I. Snizhenie vyrazhennosti simptomov nizhnih mochevyvodyashchih putej s sohraneniem seksual'noj funkcii pacientov // Vestnik Rossijskogo obshchestva urologov. 2018. № 4. S. 6–7.
8. Murashko V.V., Strutynskij A.V. EHlektrokardiografiya. M.: MEDpress-inform. 2004. 314 s.
9. Nazarenko G.I., Kishkun A.A. Klinicheskaya ocenka rezul'tatov laboratornyh issledovanij. M.: Medicina. 2000. 542 s.
10. Lobkarev A.O. Kalievyj parametr laboratornogo analiza, opredelyaemyj v ehyakulyate (KAPLEE) // Medicus. 2018. № 6. S. 53–63. 
11. Gajdyshev I.P. Modelirovanie stohasticheskih i determinirovannyh sistem: rukovodstvo pol'zovatelya programmy AtteStat. Kurgan. 2015. 484 s. 
12. Glanc S. Mediko-biologicheskaya statistika: Per. s angl. M.: Praktika. 1998. 459 s. 
13. Lobkarev A.O., Hafiz'yanova R.H., Lobkarev O.A. Neizuchennye zakonomernosti klinicheskoj ehffektivnosti tadalafila u muzhchin s ehrektil'noj disfunkciej v sochetanii s hronicheskim nevospalitel'nym prostatitom // Prakticheskaya medicina. 2018. T. 16. № 9. S. 136–140. 
14. Lobkarev A.O. Hafiz'yanova R.H., Lobkarev O.A. Sravnitel'nyj analiz klinicheskoj ehffektivnosti α1-adrenoblokatorov doksazozina, tamsulozina i silodozina u muzhchin s hronicheskim nevospalitel'nym prostatitom // Kazanskij medicinskij zhurnal. 2018. T. 99. № 6. S. 880–886.  DOI: 10.17816/kmj2018-880.
15. Thurmond P., Yang J.H., Li Y., Lerner L.B., Azadzoi K. Structural modifications of the prostate in hypoxia, oxidative stress, and chronic ischemia // Korean J. Urol. 2015. № 56. P. 187–196. DOI: 10.4111/kju.2015.56.3.187.
16. Thurmond P., Yang J.H., Azadzoi K.M. LUTS in pelvic ischemia: a new concept in voiding dysfunction // Am. J. Physiol. Renal. Physiol. 2016.  № 310. P. F738–F743. DOI: 10.1152/ajprenal.00333.2015.